Q1

Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announces a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to address […]

Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders Read More »

KKR and Taiyo Holdings Agree to Privatization to Accelerate Long-Term Growth

KKR, a leading global investment firm, and Taiyo Holdings Co., Ltd. (“Taiyo Holdings” or the “Company”; TSE stock code 4626), announce that KJ005 Co., Ltd. (the “Offeror”), an entity owned by investment funds managed by KKR, intends to make a tender offer to acquire all the common shares of Taiyo Holdings (the “Tender Offer”). Taiyo

KKR and Taiyo Holdings Agree to Privatization to Accelerate Long-Term Growth Read More »

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology Read More »

Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility in Rockville, Maryland

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announces the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States. The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical

Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility in Rockville, Maryland Read More »

Scroll to Top